Project Grant R01AI183902
Award Date
4/24/25
Completion Date
3/31/30
Dollars Obligated
$1.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $270,176 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Oncosting, LLC's development of advanced BCG vaccine candidates, OS-101 and OS-151. These recombinant BCG strains are engineered to overexpress a STING agonist, with the goal of enhancing anti-tuberculosis immunity and inducing "trained immunity" in macrophages for improved protective efficacy and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to better understand the differences in protective efficacy between different Bacillus Calmette-Guérin (BCG) vaccine sub-strains used to prevent tuberculosis (TB). The $749,192 award, spanning from November 2024 to October 2029, will enable Texas A&M University System Health Science Center (TAMU HSC)...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The primary objectives are to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in controlling TB infection and reactivation, as well as characterize the cellular mechanisms...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a comprehensive $2,817,044 research program to study the systems genetics of tuberculosis (TB). The primary grantee, the University of Massachusetts Medical School, is leading a collaborative effort with several sub-awardees, including Harvard T.H. Chan School of Public Health, University of North Carolina at...
The federal Project Grant award R01AI184623, with a total funding amount of $1,091,124.00 and an award date of July 9, 2024, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to understand the mechanisms of efficient control of Mycobacterium tuberculosis (MTB) in the lungs prior to granuloma formation, with a goal of developing novel vaccination strategies to...
This $899,894 Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate early immune cell interactions and signaling pathways that contribute to tuberculosis (TB) disease outcomes during HIV/TB co-infection. The primary awardee, The Washington University in St. Louis, will lead studies to define the roles of type I interferon (IFN) signaling and...
This federal Project Grant award of $1,185,782.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform global tuberculosis (TB) research by accelerating the study of human TB lung tissue. The primary goals are to provide two key services to the TB research community: (1) performing pathological, cellular, structural, and/or genetic analysis of resected human TB or postmortem...
The $193,316 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on the relationship between HIV exposure, contact networks, and tuberculosis (TB) in children under 5 years old. The award was made on August 20, 2024 to the Boston Medical Center Corporation, a major academic medical center, and will run through July 31, 2029. A sub-award of this grant was made to...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $517,185 award, with a performance period from August 1, 2024 to June 30, 2026, will fund research to characterize the immune response to tuberculosis (TB) using integrated single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping. The project will generate multi-omic data, including...
This $817,405 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop new 3-4 drug regimens for the treatment of drug-sensitive and drug-resistant tuberculosis (TB). The primary goals are to (1) manufacture and characterize dry powder formulations of the spectinamide compound LEE-1810 for inhalation delivery, (2) determine the optimal dose and dosing frequency of the BPAS...